Events, By Category and Date:
» Go to news mainFair pricing of “old” orphan drugs: considerations for Canada’s orphan drug policy
Posted by nte on
February 23, 2023
in
In Print
Roberts EA, Herder M, & Hollis A. (17 Apr 2015). Fair pricing of “old” orphan drugs: considerations for Canada’s orphan drug policy. CMAJ, 187(6):422-425. https://doi.org/10.1503/cmaj.140308
Recent News
- On what basis did Health Canada approve OxyContin in 1996? A retrospective analysis of regulatory data
- Matthew Herder Resigns from Patented Medicine Prices Review Board
- Permissive regulation: A critical review of the regulatory history of buprenorphine formulations in Canada
- Fair pricing of “old” orphan drugs: considerations for Canada’s orphan drug policy
- Podcast or Perish: Episode 040: Françoise Baylis
- Bioethicist Françoise Baylis asks why humans think 'they can just take everything'
- Killam Prize winners discuss research in Canada
- World‑renowned Dalhousie bioethicist and battery pioneer win prestigious Killam Prize